Weight loss and improvements in cardiometabolic outcomes with extended-release phentermine/topiramate treatment in overweight/obese subjects with type 2 diabetes

被引：0

作者：

Astrup, A. V. ^{[1
]}

Oppert, J. -M. ^{[2
]}

Peterson, C. A. ^{[3
]}

机构：

[1] Univ Copenhagen, LIFE, Dept Human Nutr, Frederiksberg, Denmark

[2] Univ Paris 06, Dept Nutr, Paris, France

[3] Vivus Inc, Mountain View, CA USA

来源：

DIABETOLOGIA | 2012年 / 55卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

695

引用

页码：S284 / S285

页数：2

共 50 条

[21] Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release
Guo, Fangjian
Garvey, W. Timothy
DIABETES CARE, 2017, 40 (07) : 856 - 862
[22] IMPROVEMENTS IN QUALITY OF LIFE BY MAGNITUDE OF WEIGHT LOSS IN OBESE AND OVERWEIGHT SUBJECTS
Church, Timothy
Troupin, Barbara
JOURNAL OF GENERAL INTERNAL MEDICINE, 2013, 28 : S105 - S105
[23] Topiramate decreases weight and blood pressure in obese subjects with type 2 diabetes
Stenlof, K
Rossner, S
Vercruysse, F
Perry, B
Fitchet, M
Sjostrom, L
OBESITY RESEARCH, 2003, 11 : A113 - A113
[24] Association of Hypoglycemic Treatment Regimens With Cardiovascular Outcomes in Overweight and Obese Subjects With Type 2 Diabetes
Ghotbi, Adam Ali
Kober, Lars
Finer, Nick
James, W. Philip T.
Sharma, Arya M.
Caterson, Ian
Coutinho, Walmir
Van Gaal, Luc F.
Torp-Pedersen, Christian
Andersson, Charlotte
DIABETES CARE, 2013, 36 (11) : 3746 - 3753
[25] Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes
Stenlof, K.
Rossner, S.
Vercruysse, F.
Kumar, A.
Fitchet, M.
Sjostrom, L.
DIABETES OBESITY & METABOLISM, 2007, 9 (03): : 360 - 368
[26] Decreased progression to diabetes in subjects with prediabetes after 2 years of treatment with controlled-release phentermine/topiramate
Garvey, W. T.
Troupin, B.
Day, W. W.
DIABETOLOGIA, 2011, 54 : S371 - S371
[27] Changes in Glycemic Parameters and Antidiabetic Medication Use by Degree of Weight Loss (WL) With Lifestyle Modification and Phentermine/Topiramate Extended-Release (PHEN/TPM ER)
Kushner, Robert
Troupin, Barbara
DIABETES, 2013, 62 : A544 - A545
[28] A Low-Dose, Controlled-Release Formulation of Phentermine/Topiramate (PHEN/TPM) Demonstrates Significant Weight Loss, Clinical Improvement in Overweight/Obese Patients with Type 2 Diabetes Mellitus (T2DM) or Prediabetes
Gadde, Kishore
Najarian, Thomas
Day, Wesley W.
DIABETES, 2010, 59 : A101 - A101
[29] EFFECTS OF PHENTERMINE AND TOPIRAMATE EXTENDED-RELEASE (PHEN/TPM ER) TREATMENT ON WEIGHT LOSS (WL) WHEN STRATIFIED BY BASELINE BODY MASS INDEX (BMI) OVER 1 YEAR
Ryan, D.
Church, T.
Karnawat, S.
Troupin, B.
VALUE IN HEALTH, 2013, 16 (03) : A112 - A112
[30] A combination of weight loss therapies for overweight subjects with type 2 diabetes mellitus
Raatz, S
Reck, K
Kwong, C
Redmon, JB
Swanson, J
Fan, Q
Thomas, W
Bantle, JP
DIABETES, 2002, 51 : A413 - A414

← 1 2 3 4 5 →